Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.

Issue 19, 2018
Previous Article Next Article

Applications of tumor chip technology

Author affiliations


Over the past six decades the inflation-adjusted cost to bring a new drug to market has been increasing constantly and doubles every 9 years – now reaching in excess of $2.5 billion. Overall, the likelihood of FDA approval for a drug (any disease indication) that has entered phase I clinical trials is a mere 9.6%, with the approval rate for oncology far below average at only 5.1%. Lack of efficacy or toxicity is often not revealed until the later stages of clinical trials, despite promising preclinical data. This indicates that the current in vitro systems for drug screening need to be improved for better predictability of in vivo outcomes. Microphysiological systems (MPS), or bioengineered 3D microfluidic tissue and organ constructs that mimic physiological and pathological processes in vitro, can be leveraged across preclinical research and clinical trial stages to transform drug development and clinical management for a range of diseases. Here we review the current state-of-the-art in 3D tissue-engineering models developed for cancer research, with a focus on tumor-on-a-chip, or tumor chip, models. From our viewpoint, tumor chip systems can advance innovative medicine to ameliorate the high failure rates in anti-cancer drug development and clinical treatment.

Graphical abstract: Applications of tumor chip technology

Back to tab navigation

Article information

31 Mar 2018
11 Aug 2018
First published
14 Aug 2018

Lab Chip, 2018,18, 2893-2912
Article type
Critical Review

Applications of tumor chip technology

S. J. Hachey and C. C. W. Hughes, Lab Chip, 2018, 18, 2893
DOI: 10.1039/C8LC00330K

Social activity

Search articles by author